As a global leader in tissue engineering, Biosolution Co.,
Ltd. specializes in the R&D of cell therapy products and human tissue models.
We have received product approval for the autologous keratinocyte therapy product KeraHeal in 2006, and the allogeneic keratinocyte therapy product KeraHeal-Allo in 2015. We are preparing for the product approval for the autologous chondrocyte therapy product CartiLife.
The human tissue models developed using our tissue engineering technology and our technology to separate and culture various cells from human tissue are used as alternatives to animal testing for toxicity and efficacy evaluation on cosmetics and pharmaceuticals.
We have developed toxicity/efficacy evaluation tests using our human tissue models to register our human tissue models as OECD standard models. We are performing qualification tests that are led by the NIFDS.
Along with our human tissue models, contracted research services using our human tissue models are provided by us as well. We will make sure to provide accurate and reliable solutions in in vitro non-clinical trials on cosmetics, medical devices, pharmaceuticals etc.